Search Results - "DEAN, Emma"

The role of general practice nurses in supporting people to quit smoking: A qualitative study by Jongebloed, Hannah, Cole, Eileen, Dean, Emma, Ugalde, Anna

“…Encounters with General Practitioners (GPs) have previously been identified as opportune for the delivery of smoking cessation care however the role of nurses…”
Get full text

Using Administrative Data to Examine Telemedicine Usage Among Medicaid Beneficiaries During the Coronavirus Disease 2019 Pandemic by Hossain, Mallick, Dean, Emma B., Kaliski, Daniel

“…The coronavirus disease 2019 (COVID-19) pandemic necessitated the replacement of in-person physician consultations with telemedicine. During the pandemic,…”
Get full text

Financial Incentives In Biosimilar Uptake/The Authors Reply by Testoni, Maureen, Bond, Amelia M, Dean, Emma B, Desai, Sunita

Get full text

Government Fragmentation and Public Goods Provision by Grossman, Guy, Pierskalla, Jan H., Dean, Emma Boswell

“…We investigate the effects of territorial government fragmentation on the quality of public services. We argue that an increase in the number of regional…”
Get full text

The Role Of Financial Incentives In Biosimilar Uptake In Medicare: Evidence From The 340B Program by Bond, Amelia M, Dean, Emma B, Desai, Sunita M

“…Biosimilar drugs-lower-cost alternatives to expensive biologic drugs-have the potential to slow the growth of US drug spending. However, rates of biosimilar…”
Get full text

Occupancy maps of 208 chromatin-associated proteins in one human cell type by Partridge, E. Christopher, Chhetri, Surya B., Prokop, Jeremy W., Ramaker, Ryne C., Jansen, Camden S., Goh, Say-Tar, Mackiewicz, Mark, Newberry, Kimberly M., Brandsmeier, Laurel A., Meadows, Sarah K., Messer, C. Luke, Hardigan, Andrew A., Coppola, Candice J., Dean, Emma C., Jiang, Shan, Savic, Daniel, Mortazavi, Ali, Wold, Barbara J., Myers, Richard M., Mendenhall, Eric M.

“…Transcription factors are DNA-binding proteins that have key roles in gene regulation 1 , 2 . Genome-wide occupancy maps of transcriptional regulators are…”
Get full text

Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study by Rothwell, Dominic G., Ayub, Mahmood, Cook, Natalie, Thistlethwaite, Fiona, Carter, Louise, Dean, Emma, Smith, Nigel, Villa, Shaun, Dransfield, Joanne, Clipson, Alexandra, White, Daniel, Nessa, Kamrun, Ferdous, Saba, Howell, Matthew, Gupta, Avinash, Kilerci, Bedirhan, Mohan, Sumitra, Frese, Kris, Gulati, Sakshi, Miller, Crispin, Jordan, Allan, Eaton, Helen, Hickson, Nicholas, O’Brien, Ciara, Graham, Donna, Kelly, Claire, Aruketty, Sreeja, Metcalf, Robert, Chiramel, Jaseela, Tinsley, Nadina, Vickers, Alexander J., Kurup, Roopa, Frost, Hannah, Stevenson, Julie, Southam, Siobhan, Landers, Dónal, Wallace, Andrew, Marais, Richard, Hughes, Andrew M., Brady, Ged, Dive, Caroline, Krebs, Matthew G.

“…Sequencing of circulating tumor DNA from cancer patients is a cost-efficient approach with turnaround time compatible with clinical practice to inform…”
Get full text

Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells by Lloyd, Rebecca L., Wijnhoven, Paul W. G., Ramos-Montoya, Antonio, Wilson, Zena, Illuzzi, Giuditta, Falenta, Katarzyna, Jones, Gemma N., James, Neil, Chabbert, Christophe D., Stott, Jonathan, Dean, Emma, Lau, Alan, Young, Lucy A.

“…The poly (ADP-ribose) polymerase (PARP) inhibitor olaparib is FDA approved for the treatment of BRCA -mutated breast, ovarian and pancreatic cancers. Olaparib…”
Get full text

AKT Inhibition in Solid Tumors With AKT1 Mutations by Hyman, David M, Smyth, Lillian M, Donoghue, Mark T A, Westin, Shannon N, Bedard, Philippe L, Dean, Emma J, Bando, Hideaki, El-Khoueiry, Anthony B, Pérez-Fidalgo, José A, Mita, Alain, Schellens, Jan H M, Chang, Matthew T, Reichel, Jonathan B, Bouvier, Nancy, Selcuklu, S Duygu, Soumerai, Tara E, Torrisi, Jean, Erinjeri, Joseph P, Ambrose, Helen, Barrett, J Carl, Dougherty, Brian, Foxley, Andrew, Lindemann, Justin P O, McEwen, Robert, Pass, Martin, Schiavon, Gaia, Berger, Michael F, Chandarlapaty, Sarat, Solit, David B, Banerji, Udai, Baselga, José, Taylor, Barry S

“…Purpose AKT1 E17K mutations are oncogenic and occur in many cancers at a low prevalence. We performed a multihistology basket study of AZD5363, an…”
Get full text

A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA -Mutated Breast and Gynecologic Cancers by Banerji, Udai, Dean, Emma J, Pérez-Fidalgo, J Alejandro, Batist, Gerald, Bedard, Philippe L, You, Benoit, Westin, Shannon N, Kabos, Peter, Garrett, Michelle D, Tall, Mathew, Ambrose, Helen, Barrett, J Carl, Carr, T Hedley, Cheung, S Y Amy, Corcoran, Claire, Cullberg, Marie, Davies, Barry R, de Bruin, Elza C, Elvin, Paul, Foxley, Andrew, Lawrence, Peter, Lindemann, Justin P O, Maudsley, Rhiannon, Pass, Martin, Rowlands, Vicky, Rugman, Paul, Schiavon, Gaia, Yates, James, Schellens, Jan H M

“…This phase I, open-label study (Study 1, D3610C00001; NCT01226316) was the first-in-human evaluation of oral AZD5363, a selective pan-AKT inhibitor, in…”
Get full text

What is the likely impact on surgical site infections in Australian hospitals if smoking rates are reduced? A cost analysis by McCaffrey, Nikki, Scollo, Michelle, Dean, Emma, White, Sarah L

“…Assisting smokers to quit before surgery reduces surgical site infection (SSI) risk. The short-term economic benefits of reducing SSIs by embedding tobacco…”
Get full text

Food insecurity, health care utilization, and health care expenditures by Dean, Emma Boswell, French, Michael T., Mortensen, Karoline

“…Objective To disentangle the relationships among food insecurity, health care utilization, and health care expenditures. Data Sources/Study Setting We use…”
Get full text

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors by Falchook, Gerald, Infante, Jeffrey, Arkenau, Hendrik-Tobias, Patel, Manish R., Dean, Emma, Borazanci, Erkut, Brenner, Andrew, Cook, Natalie, Lopez, Juanita, Pant, Shubham, Frankel, Arthur, Schmid, Peter, Moore, Kathleen, McCulloch, William, Grimmer, Katharine, O'Farrell, Marie, Kemble, George, Burris, Howard

“…We conducted a first-in-human dose-escalation study with the oral FASN inhibitor TVB-2640 to determine the maximum tolerated dose (MTD) and recommended phase 2…”
Get full text

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014 by Basu, Bristi, Dean, Emma, Puglisi, Martina, Greystoke, Alastair, Ong, Michael, Burke, Wendy, Cavallin, Maria, Bigley, Graham, Womack, Christopher, Harrington, Elizabeth A, Green, Stephen, Oelmann, Elisabeth, de Bono, Johann S, Ranson, Malcolm, Banerji, Udai

“…AZD2014 is a novel, oral, m-TORC 1/2 inhibitor that has shown in vitro and in vivo efficacy across a range of preclinical human cancer models. A rolling…”
Get full text

The Discovery of 7‑Methyl-2-[(7-methyl[1,2,4]triazolo[1,5‑a]pyridin-6-yl)amino]-9-(tetrahydro‑2H‑pyran-4-yl)-7,9-dihydro‑8H‑purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor by Goldberg, Frederick W, Finlay, M. Raymond V, Ting, Attilla K. T, Beattie, David, Lamont, Gillian M, Fallan, Charlene, Wrigley, Gail L, Schimpl, Marianne, Howard, Martin R, Williamson, Beth, Vazquez-Chantada, Mercedes, Barratt, Derek G, Davies, Barry R, Cadogan, Elaine B, Ramos-Montoya, Antonio, Dean, Emma

“…DNA-PK is a key component within the DNA damage response, as it is responsible for recognizing and repairing double-strand DNA breaks (DSBs) via non-homologous…”
Get full text

Hospital staff perspectives on the provision of smoking cessation care: a qualitative description study by Russell, Lahiru, Whiffen, Rachel, Chapman, Lorena, Just, Jasmine, Dean, Emma, Ugalde, Anna, White, Sarah

“…To explore the perspectives of hospital staff regarding the provision of smoking cessation care. A qualitative description study using focus group discussions…”
Get full text

Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response by Willis, Sophie E., Winkler, Claudia, Roudier, Martine P., Baird, Tarrion, Marco-Casanova, Paola, Jones, Emma V., Rowe, Philip, Rodriguez-Canales, Jaime, Angell, Helen K., Ng, Felicia S. L., Waring, Paul M., Hodgson, Darren, Ledermann, Jonathan A., Weberpals, Johanne I., Dean, Emma, Harrington, Elizabeth A., Barrett, J. Carl, Pierce, Andrew J., Leo, Elisabetta, Jones, Gemma N.

“…Background The absence of the putative DNA/RNA helicase Schlafen11 (SLFN11) is thought to cause resistance to DNA-damaging agents (DDAs) and PARP inhibitors…”
Get full text

The ATR inhibitor ceralasertib potentiates cancer checkpoint immunotherapy by regulating the tumor microenvironment by Hardaker, Elizabeth L., Sanseviero, Emilio, Karmokar, Ankur, Taylor, Devon, Milo, Marta, Michaloglou, Chrysis, Hughes, Adina, Mai, Mimi, King, Matthew, Solanki, Anisha, Magiera, Lukasz, Miragaia, Ricardo, Kar, Gozde, Standifer, Nathan, Surace, Michael, Gill, Shaan, Peter, Alison, Talbot, Sara, Tohumeken, Sehmus, Fryer, Henderson, Mostafa, Ali, Mulgrew, Kathy, Lam, Carolyn, Hoffmann, Scott, Sutton, Daniel, Carnevalli, Larissa, Calero-Nieto, Fernando J., Jones, Gemma N., Pierce, Andrew J., Wilson, Zena, Campbell, David, Nyoni, Lynet, Martins, Carla P., Baker, Tamara, Serrano de Almeida, Gilberto, Ramlaoui, Zainab, Bidar, Abdel, Phillips, Benjamin, Boland, Joseph, Iyer, Sonia, Barrett, J. Carl, Loembé, Arsene-Bienvenu, Fuchs, Serge Y., Duvvuri, Umamaheswar, Lou, Pei-Jen, Nance, Melonie A., Gomez Roca, Carlos Alberto, Cadogan, Elaine, Critichlow, Susan E., Fawell, Steven, Cobbold, Mark, Dean, Emma, Valge-Archer, Viia, Lau, Alan, Gabrilovich, Dmitry I., Barry, Simon T.

“…The Ataxia telangiectasia and Rad3-related (ATR) inhibitor ceralasertib in combination with the PD-L1 antibody durvalumab demonstrated encouraging clinical…”
Get full text

Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer by Kwon, Minsuk, Kim, Gahyun, Kim, Ryul, Kim, Kyu-Tae, Kim, Seung Tae, Smith, Simon, Mortimer, Peter G S, Hong, Jung Yong, Loembé, Arsene-Bienvenu, Irurzun-Arana, Itziar, Koulai, Loumpiana, Kim, Kyoung-Mee, Kang, Won Ki, Dean, Emma, Park, Woong-Yang, Lee, Jeeyun

“…BackgroundTargeting the DNA damage repair (DDR) pathways is an attractive strategy for boosting cancer immunotherapy. Ceralasertib (AZD6738) is an oral kinase…”
Get full text

Bone marrow Tregs mediate stromal cell function and support hematopoiesis via IL-10 by Camacho, Virginia, Matkins, Victoria R, Patel, Sweta B, Lever, Jeremie M, Yang, Zhengqin, Ying, Li, Landuyt, Ashley E, Dean, Emma C, George, James F, Yang, Henry, Ferrell, Paul Brent, Maynard, Craig L, Weaver, Casey T, Turnquist, Heth R, Welner, Robert S

“…The nonimmune roles of Tregs have been described in various tissues, including the BM. In this study, we comprehensively phenotyped marrow Tregs, elucidating…”
Get full text